Table 1 Treatment parameters and patient characteristics for all treatment groups
From: Hypofractionated versus standard fractionation radiotherapy for merkel cell carcinoma
Stratification | |||||
|---|---|---|---|---|---|
Palliative (N = 6) | Post-op and Def 2 Gy/fx (N = 13) | Post-op and Def 4 Gy/fx (N = 10) | Total (N = 29) | P-value | |
Area, cm2 | 0.8701 | ||||
N | 4 | 8 | 10 | 22 | |
Mean (SD) | 306.3 (464.09) | 94.8 (47.54) | 97.1 (30.60) | 134.3 (197.00) | |
Median | 102.5 | 76.6 | 92.1 | 92.1 | |
Range | 20.3, 1000.0 | 42.3, 183.8 | 52.0, 141.8 | 20.3, 1000.0 | |
RT Total Dose, Gy | < .0011 | ||||
N | 6 | 13 | 10 | 29 | |
Mean (SD) | 8.0 (0.00) | 55.9 (4.27) | 36.4 (10.06) | 39.3 (19.53) | |
Median | 8.0 | 56.0 | 40.0 | 40.0 | |
Range | 8.0, 8.0 | 50.0, 60.0 | 16.0, 48.0 | 8.0, 60.0 | |
RT Total Fractions, fx | < .0011 | ||||
N | 6 | 13 | 10 | 29 | |
Mean (SD) | 1.0 (0.00) | 28.4 (1.76) | 9.1 (2.51) | 16.1 (11.82) | |
Median | 1.0 | 28.0 | 10.0 | 10.0 | |
Range | 1.0, 1.0 | 25.0, 30.0 | 4.0, 12.0 | 1.0, 30.0 | |
RT Type, n (%) | < .0012 | ||||
3D | 3 (50.0%) | 0 (0.0%) | 0 (0.0%) | 3 (10.3%) | |
Electrons + VMAT | 3 (50.0%) | 4 (30.8%) | 10 (100.0%) | 17 (58.6%) | |
Protons | 0 (0.0%) | 6 (46.2%) | 0 (0.0%) | 6 (20.7%) | |
VMAT | 0 (0.0%) | 3 (23.1%) | 0 (0.0%) | 3 (10.3%) | |
Location Category, n (%) | 0.6062 | ||||
H&N | 3 (50.0%) | 8 (61.5%) | 4 (40.0%) | 15 (51.7%) | |
Lower Extremity | 0 (0.0%) | 1 (7.7%) | 2 (20.0%) | 3 (10.3%) | |
Trunk | 2 (33.3%) | 1 (7.7%) | 1 (10.0%) | 4 (13.8%) | |
Upper Extremity | 1 (16.7%) | 3 (23.1%) | 3 (30.0%) | 7 (24.1%) | |
Primary or recurrent, n (%) | 0.0232 | ||||
Primary | 2 (33.3%) | 11 (84.6%) | 9 (90.0%) | 22 (75.9%) | |
Recurrent | 4 (66.7%) | 2 (15.4%) | 1 (10.0%) | 7 (24.1%) | |
Nodal Status, n (%) | < .0012 | ||||
Negative | 0 (0.0%) | 2 (15.4%) | 6 (60.0%) | 8 (27.6%) | |
Positive | 1 (16.7%) | 11 (84.6%) | 1 (10.0%) | 13 (44.8%) | |
Unknown (Nx) | 5 (83.3%) | 0 (0.0%) | 3 (30.0%) | 8 (27.6%) | |
ECOG, n (%) | 0.2542 | ||||
0 | 0 (0.0%) | 6 (46.2%) | 4 (40.0%) | 10 (34.5%) | |
1 | 3 (50.0%) | 6 (46.2%) | 2 (20.0%) | 11 (37.9%) | |
2 | 2 (33.3%) | 1 (7.7%) | 3 (30.0%) | 6 (20.7%) | |
3 | 1 (16.7%) | 0 (0.0%) | 1 (10.0%) | 2 (6.9%) | |
Acute Dermatits Grade, n (%) | 0.0062 | ||||
0 | 5 (83.3%) | 0 (0.0%) | 3 (30.0%) | 8 (27.6%) | |
1 | 1 (16.7%) | 4 (30.8%) | 4 (40.0%) | 9 (31.0%) | |
2 | 0 (0.0%) | 5 (38.5%) | 3 (30.0%) | 8 (27.6%) | |
3 | 0 (0.0%) | 4 (30.8%) | 0 (0.0%) | 4 (13.8%) | |
Other Acute Toxicity G2+, n (%) | 0.1902 | ||||
(G2) dysgeusia | 0 (0.0%) | 1 (7.7%) | 0 (0.0%) | 1 (3.4%) | |
(G2) fatigue | 0 (0.0%) | 0 (0.0%) | 1 (10.0%) | 1 (3.4%) | |
(G2) skin ulceration | 2 (33.3%) | 0 (0.0%) | 0 (0.0%) | 2 (6.9%) | |
Edema limbs (G3), (G2) esophagitis | 0 (0.0%) | 1 (7.7%) | 0 (0.0%) | 1 (3.4%) | |
G2 xerostomia, G2 dysgeusia | 0 (0.0%) | 0 (0.0%) | 1 (10.0%) | 1 (3.4%) | |
G3 skin ulceration, G2 pain | 1 (16.7%) | 0 (0.0%) | 0 (0.0%) | 1 (3.4%) | |
dental caries | 0 (0.0%) | 1 (7.7%) | 0 (0.0%) | 1 (3.4%) | |
fatigue (2) | 0 (0.0%) | 1 (7.7%) | 0 (0.0%) | 1 (3.4%) | |
n/a | 3 (50.0%) | 9 (69.2%) | 8 (80.0%) | 20 (69.0%) | |
Time duration of RT, days | < .0011 | ||||
N | 6 | 13 | 9 | 28 | |
Mean (SD) | 0.0 (0.00) | 39.2 (3.37) | 41.4 (44.06) | 31.5 (29.37) | |
Median | 0.0 | 39.0 | 25.0 | 35.0 | |
Range | 0.0, 0.0 | 34.0, 45.0 | 14.0, 156.0 | 0.0, 156.0 | |
Time sim to end of RT, days | < .0011 | ||||
N | 6 | 13 | 9 | 28 | |
Mean (SD) | 6.5 (4.59) | 55.5 (6.28) | 53.9 (44.31) | 44.5 (31.80) | |
Median | 7.0 | 54.0 | 39.0 | 50.0 | |
Range | 0.0, 13.0 | 46.0, 70.0 | 24.0, 167.0 | 0.0, 167.0 | |
Time surgery to sim, days | 0.0291 | ||||
N | 3 | 11 | 10 | 24 | |
Mean (SD) | 662.3 (383.50) | 128.0 (234.51) | 30.6 (6.72) | 154.2 (278.15) | |
Median | 662.0 | 32.0 | 29.5 | 32.5 | |
Range | 279.0, 1046.0 | 18.0, 811.0 | 21.0, 41.0 | 18.0, 1046.0 | |